Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 4:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Healthy Volunteers
Interventions: Aspirin, BMS-986177, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Fluticasone Propionate/Formoterol Fumarate, Fluticasone Propionate, Formoterol Fumarate, Fluticasone Propionate/Salmeterol Xinafoate, Placebo; Drug
Lead sponsor: Dey; Industry
Eligibility: 40 Years and older
Enrollment: 457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 49
States / cities: Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 44 more

Conditions: Non-Small Cell Lung Cancer
Interventions: MEDI4736, PLACEBO; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 713 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 60
States / cities: Chandler, Arizona • Goodyear, Arizona • Jonesboro, Arkansas + 53 more

Conditions: Breathing-Related Sleep Disorder
Interventions: AVAPS-AE Non-invasive ventilation therapy; Device
Lead sponsor: Philips Respironics; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Colorectal Carcinoma, Gastric Carcinoma, Pancreatic Ductal Adenocarcinoma
Interventions: BI 765049; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 1 more

Conditions: Graft-versus-Host Disease, Immune System Disorders
Interventions: Mycophenolate Mofetil, Placebo; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: Not listed
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 36
States / cities: Duarte, California • La Jolla, California • Stanford, California + 28 more

Conditions: Menopause
Interventions: esterified estrogens 0.625 mg and methyltestosterone 1.25 mg; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 77
States / cities: Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 74 more

Conditions: Hemorrhoids
Interventions: Transanal hemorrhoid dearterialization, Ferguson hemorrhoidectomy; Device · Procedure
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Congenital Bleeding Disorder, Haemophilia A
Interventions: turoctocog alfa; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 18
States / cities: Little Rock, Arkansas • Long Beach, California • Tampa, Florida + 15 more

Conditions: Persistent Nonvalvular Atrial Fibrillation
Interventions: Certoparin; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Parkinson Disease
Interventions: Deep Brain Stimulation, STN, GP Deep Brain Stimulation; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 89 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hematologic Disease, Blood Coagulation Disorders
Interventions: Recombinant Factor VIII (Kogenate, BAY 14-2222); Behavioral
Lead sponsor: Bayer; Industry
Eligibility: 14 Years to 29 Years · Male only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 7
States / cities: Duarte, California • Denver, Colorado • Peoria, Illinois + 4 more

Conditions: Macular Degeneration
Interventions: RO6867461; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 5
States / cities: Colorado Springs, Colorado • Baltimore, Maryland • Dallas, Texas + 2 more

Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions: INR731, Enzalutamide, Abiraterone, Androgen deprivation therapy (ADT); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts • Dallas, Texas

Conditions: Respiratory Syncytial Virus Infection, Healthy Volunteers, Metapneumovirus Infection
Interventions: RSV/hMPV mRNA LNP 1, RSV/hMPV mRNA LNP 2, RSV mRNA LNP 1, hMPV mRNA LNP 1; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 558 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 9
States / cities: Gardena, California • Hallandale, Florida • Meridian, Idaho + 6 more

Conditions: Kidney Transplantation
Interventions: FCR001; Biological
Lead sponsor: Talaris Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • Minneapolis, Minnesota

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Daytrana; Drug
Lead sponsor: Noven Therapeutics; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 29
States / cities: Scottsdale, Arizona • Irvine, California • San Marcos, California + 26 more

Conditions: Prostate Neoplasms
Interventions: ASG-5ME; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 4
States / cities: Baltimore, Maryland • Detriot, Michigan • New York, New York + 1 more

Conditions: Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Autoimmune Encephalitis, Celiac Disease, Celiac Disease in Children, Chronic Lyme Disease, Post-treatment Lyme Disease Syndrome, Crohn's Disease, Dysautonomia, Anorexia Nervosa, Bulimia Nervosa, ARFID, Avoidant / Restrictive Food Intake Disorder, Ehlers Danlos Syndrome, Endometriosis, Fibromyalgia (FM), Long COVID, Lupus, Migraines, Mast Cell Activation Syndrome, Multiple Sclerosis, Myalgic Encephalomyelitis (ME), Myasthenia Gravis, Generalized, Myasthenia Gravis in Children, Narcolepsy, Obsessive Compulsive Disorder (OCD), PANDAS, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), POTS - Postural Orthostatic Tachycardia Syndrome, General Anxiety Disorder, Social Anxiety Disorder, PTSD - Post Traumatic Stress Disorder, Psoriasis, Traumatic Brain Injury, Tourette's Syndrome, Inflammatory Bowel Disease (IBD), Autoimmune Diseases, Neurological Diseases or Conditions, Psychiatric Disorder, Sjogren's Syndrome, Ulcerative Colitis and Crohn's Disease
Interventions: Not listed
Lead sponsor: Brain Inflammation Collaborative; Other
Eligibility: 2 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Delafield, Wisconsin

Conditions: Infection, Human Immunodeficiency Virus I
Interventions: Fosamprenavir; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 51
States / cities: Beverly Hills, California • Fresno, California • Laguna Beach, California + 42 more

Conditions: Metastatic Melanoma
Interventions: High Dose Interleukin-2, Ipilimumab; Drug
Lead sponsor: Clinigen, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 12
States / cities: Tucson, Arizona • La Jolla, California • Miami Beach, Florida + 9 more

Conditions: Rheumatoid Arthritis
Interventions: Tocilizumab, Adalimumab, Placebo to tocilizumab, Placebo to adalimumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 33
States / cities: Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 30 more

Conditions: High-Risk Acute Myeloid Leukemia, Treatment-Related Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: ALT-803; Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Spinal Cord Injury, Paralysis, Tetraplegia, Paraplegia
Interventions: IST-16 (16-Channel implanted stimulator-telemeter; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants

A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease

A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

A Pilot Study to Assess the Effects of a Novel Application of Averaged Volume Assured Pressure Support Ventilation (AVAPS-AE) Therapy on Re-hospitalization in Patients With Sleep-Disordered Breathing With Co-morbid COPD

A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas

Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)

Study of the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women

Multicenter Prospective Trial on Hemorrhoids

Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects

Atrial Fibrillation Feasibility Certoparin Trial - AFFECT

Multiple Objective Particle Swarm Optimization Postural Instability Gait Disorder

Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A

A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older

A Safety and Efficacy Study of FCR001 Cell Therapy in Previously Transplanted Living Donor Kidney Recipients

Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA

A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

Fosamprenavir Versus Other Protease Inhibitors

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis

QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML

A Neuroprosthesis for Prolonged Standing After SCI Using Multi-Contact Peripheral Nerve Electrodes